Home > Boards > US Listed > Medical - Drugs > Oramed Pharmaceuticals (ORMP)

Hi Thirdave,

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Spideyboy Member Profile
 
Followed By 4
Posts 607
Boards Moderated 0
Alias Born 04/07/08
160x600 placeholder
Oramed Provides Highlights and Data From Its Phase IIb Oral Insulin Study Investor Event PR Newswire (US) - 11/19/2019 8:55:00 AM
Oramed Pharmaceuticals to Discuss Positive Phase IIb Data at Investor Event and Conference Call on Monday, November 18th PR Newswire (US) - 11/14/2019 7:28:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/12/2019 7:04:56 AM
Oramed Announces Successful Phase IIb Study of Oral Insulin in Type 2 Diabetes PR Newswire (US) - 11/12/2019 7:00:00 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 10/23/2019 4:36:39 PM
Oramed to Present at Ladenburg Thalmann 2019 Healthcare Conference PR Newswire (US) - 9/18/2019 8:38:00 AM
Oramed Announces Last Patient Treated in Pivotal Phase IIb Trial of Oral Insulin ORMD-0801 PR Newswire (US) - 9/17/2019 8:40:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 6:09:08 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 6:08:27 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 6:07:48 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 9/16/2019 6:07:23 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 6:07:15 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 6:06:32 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/11/2019 5:18:02 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 9/5/2019 4:49:41 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/5/2019 4:42:36 PM
Oramed to Present at Three Upcoming Conferences PR Newswire (US) - 9/3/2019 8:25:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/21/2019 5:28:25 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 8/6/2019 1:29:52 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/29/2019 6:08:14 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 7/19/2019 12:12:05 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/18/2019 1:32:15 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/15/2019 7:03:47 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 7/10/2019 5:28:14 PM
Oramed to Present at World Diabetes Congress PR Newswire (US) - 7/10/2019 8:40:00 AM
Spideyboy   Thursday, 06/29/17 08:10:31 AM
Re: Thirdave post# 495
Post # of 520 
Hi Thirdave,

Thanks for informing about Eastgate.

While I can see there is an overall similarity in making insulin orally bioavailable, I would say Oramed is substantially a better bet. Not simply based on the clinical phase of their oral products, or their distribution deal and milestone funding from the Chinese, but also quite simply on the science.

Oramed's delivery allows the delivery of insulin to the liver via the portal vein, which mimics a natural flow of insulin. Also the patents of Oramed and Eastgate would be completely different in the method of delivery so no concerns there.

Also Oramed is only 1 clinical trial away from potential approval of ORMD-0801 Type 1 with the cash to achieve this, and with excellent safety and efficacy Phase II data. It seems Eastgate has very little information on where they are at or if they even have pre-clinical data? It generally appears Eastgate would be a decade away from a commercially available insulin product, if there is any data to show that it works.

Finally going past just insulin, the beauty of Oramed's POD technology is that really they haven't created a new drug, they've just created a great delivery system. So as per their corporate presentation, Oramed can simply swap whatever drug it wants in and out of the fundamental POD system, and create a whole new orally bioavailable drug, which previously was only available via injection.

Again given the circumstances outlined, Oramed seems the better bet, short, mid and long-term. IMHO


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist